Aethlon Medical

Aethlon Medical reported preliminary efficacy signals for its blood-filtration device Hemopurifier from an Australian oncology study at the Emerging Growth Conference, observing a possible dose–response pattern with more consistent EV reductions after multiple treatments. The company said that across roughly 150 treatments there were no device-related serious adverse events or dose-limiting toxicities. Cash on hand was about $4.9 million as of June 30, plus roughly $4 million in gross proceeds, which the company says should fund operations for at least 12 months. Aethlon plans to complete the final cohort and follow-up by the end of 2026, intends to engage with U.S. and Australian regulators, and is exploring uses such as long COVID; however, broader studies will require additional funding and regulatory feedback. » More on de.investing.com

Aethlon Medical released results for the quarter ended June 30, 2026, reporting a loss of $4.02 per share. In the same quarter a year earlier, the loss was $42,500 per share. » More on finanzen.net

At the Emerging Growth Conference Aethlon Medical showed early biological effects of the Hemopurifier in an Australian safety study: reduced extracellular vesicles, more favorable immune markers and no device-related serious adverse events so far in seven of nine patients. The company recently raised about $4 million gross proceeds, cut its burn rate by 50% and says it is debt-free with sufficient funds to complete the ongoing study and engage regulators. Next steps are finishing recruitment, statistical analysis of the data and planning larger pivotal trials; partnerships or licensing deals will be considered once stronger clinical data are available. » More on de.investing.com